公开(公告)号：US12187714B2

公开(公告)日：2025-01-07

申请号：US18328267

申请日：2023-06-02

Applicant: Yuhan Corporation

Inventor： Sang-Ho Oh ,  Ja-Heouk Khoo ,  Jong-Chul Lim ,  Seong-Ran Lee ,  Hyun Ju ,  Woo-Seob Shin ,  Dae-Gyu Park ,  Su-Min Park ,  Yoon-Ah Hwang

IPC: C07D413/14

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additionally, the present invention provides novel intermediates useful for said process and processes for preparing the same.

公开(公告)号：US20240262819A1

公开(公告)日：2024-08-08

申请号：US18559466

申请日：2022-05-10

Applicant: YUHAN CORPORATION ,  GREEN CROSS CORPORATION

Inventor： Dong-Hoon KIM ,  Jae-Eun JOO ,  Seung-Yub SHIN ,  Sool-Ki KWON ,  Jong-Suk PARK

IPC: C07D453/02 ,  A61K31/439

CPC classification number: C07D453/02 ,  A61K31/439

Abstract: Provided are a compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and exhibits the effects of alleviating symptoms in the central nervous system as well as in the peripheral nervous system, through excellent blood-brain barrier permeability, and therefore, the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

公开(公告)号：US20240238380A1

公开(公告)日：2024-07-18

申请号：US18562322

申请日：2022-05-20

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Do Hoon KIM ,  Mi Kyeong JU ,  Hyun Ho CHOI ,  Han Na HONG ,  Junhwan KIM

IPC: A61K38/26 ,  A61K38/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K38/1841 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome by administering in combination with a GLP-1 (glucagon-like peptide-1) receptor agonist, comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20230255967A1

公开(公告)日：2023-08-17

申请号：US18014262

申请日：2021-07-01

Applicant: YUHAN CORPORATION

Inventor： Dong-Min Park ,  Su-Hyeon Kim ,  Eun-Pa Cheon ,  Tae-Lin Ha ,  Jun-Mo Yang ,  Yoong-Sik Park

IPC: A61K31/506 ,  A61K9/20

CPC classification number: A61K31/506 ,  A61K9/2013 ,  A61K9/2095 ,  A61K9/2054 ,  A61K9/2027

Abstract: The present invention provides a pharmaceutical composition comprising (S)—N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide or a pharmaceutically acceptable salt thereof having an activity as a 5-HT4 receptor agonist and an acidifying agent; and a process for preparing the same.

公开(公告)号：US20230212249A1

公开(公告)日：2023-07-06

申请号：US18068506

申请日：2022-12-19

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun CHOI ,  In Hwan LIM ,  Jun Young PARK ,  Jin Hyoung LEE ,  Ki Hong KIM ,  Hae Yong JO ,  Jun Hwan KIM ,  Moo Young SONG ,  Jong Gyun KIM

IPC: C07K14/605 ,  C12P21/02 ,  C07K14/50 ,  C07K19/00 ,  C07K16/46 ,  C12N5/00 ,  C12N15/00

CPC classification number: C07K14/605 ,  C12P21/02 ,  C07K14/50 ,  C07K19/00 ,  C07K16/46 ,  C12N5/00 ,  C07K2319/30 ,  C12N15/00

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US11623925B2

公开(公告)日：2023-04-11

申请号：US17873966

申请日：2022-07-26

Applicant: YUHAN CORPORATION

Inventor： Ja-Heouk Khoo ,  Doo-Byung Lee ,  Jun-Sup Lee ,  Hyun Ju ,  Woo-Seob Shin

IPC: C07D403/04 ,  C07D239/47

Abstract: The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist. And also, the present invention provides novel crystalline forms of a hydrochloride of the diaminopyrimidine derivative and processes for preparing the same.

公开(公告)号：US11560416B2

公开(公告)日：2023-01-24

申请号：US16606279

申请日：2018-04-20

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun Choi ,  In Hwan Lim ,  Jun Young Park ,  Jin Hyoung Lee ,  Ki Hong Kim ,  Hae Yong Jo ,  Jun Hwan Kim ,  Moo Young Song ,  Jong Gyun Kim

IPC: C12N15/62 ,  C12N15/09 ,  C12N5/00 ,  C07K16/46 ,  C07K19/00 ,  C07K14/605 ,  C07K14/50 ,  C12P21/02 ,  C12N15/00

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20220024918A1

公开(公告)日：2022-01-27

申请号：US17368712

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20210322428A1

公开(公告)日：2021-10-21

申请号：US17285161

申请日：2019-10-17

Applicant: YUHAN CORPORATION

Inventor： Seongkyu KIM ,  Deokkyu LEE ,  Soo-Won KIM ,  Jun-Mo YANG ,  Yoong-Sik PARK

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/20

Abstract: The present disclosure provides a pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent.

公开(公告)号：US11091479B2

公开(公告)日：2021-08-17

申请号：US16712673

申请日：2019-12-12

Applicant: YUHAN CORPORATION

Inventor： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Dong Hoon Kim ,  Su Bin Choi ,  Sol Park ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).